New insider activity at Henry Schein ( (HSIC) ) has taken place on March 7, 2025.
Director Kurt Kuehn recently sold 3,359 shares of Henry Schein stock, amounting to a total transaction value of $239,599.
Recent Updates on HSIC stock
Henry Schein’s recent earnings call highlighted a mix of strategic achievements and operational challenges. The company exceeded its BOLD+1 strategic goal of generating 40% of worldwide operating income from high-growth, high-margin businesses by 2024, underscoring its focus on profitable sectors. Strong performance was noted in the Global Specialty Products Group, particularly in dental implants, biomaterials, and endodontics, and U.S. dental equipment sales surged with double-digit growth. However, challenges were observed in the orthodontic segment due to a key product going off patent, and the U.S. medical business struggled with a late flu season and lower vaccine and PPE sales. Flat patient traffic also posed a challenge, contributing to lower-than-expected revenue growth of 5.8% for Q4, falling short of guidance. Despite these hurdles, the company remains optimistic, projecting sales growth of 2% to 4% in 2025 and leveraging cost savings from restructuring initiatives to support future growth. The sentiment remains cautiously optimistic, with a focus on strategic adjustments to address market conditions and segment challenges.
More about Henry Schein
YTD Price Performance: 4.25%
Average Trading Volume: 1,839,682
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.73B